Harpoon Therapeutics - About the company
Harpoon Therapeutics is an acquired company based in Cambridge (United States), founded in 2015. It operates as a Developer of T-cell antibodies against hematologic and solid tumor targets. Harpoon Therapeutics has raised $130M in funding from investors like Arix Bioscience, Orbimed and New Leaf Venture Partners, with last known valuation of $*****. The company has 3372 active competitors, including 1136 funded and 786 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Harpoon Therapeutics is a preclinical stage company focussed on developing a class of T cell recruiting antibodies against validated hematologic and solid tumor targets. It is currently screening its discovered programs and is advancing them into preclinical trials for a broad range of cancer indications.
- Website
- harpoontx.com
- Social
- Registered Address
- 131 Oyster Point Blvd, Suite 300 South San Francisco, CA 940
Key Metrics
Founded Year
2015
Location
Cambridge, United States
Stage
Acquired
Total Funding
$130M in 5 rounds
Latest Funding Round
Last Known Valuation
$***** as on Jan 08, 2024
Investors
Ranked
779th among 3372 active competitors
Annual Revenue
$25M - $100M as on Apr 07, 2023
Employee Count
10 - 49 as on Mar 01, 2026
Similar Companies
Exit Details
Acquired by Merck Sharp & Dohme (Jan 08, 2024)
Legal entities associated with Harpoon Therapeutics
Harpoon Therapeutics is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Harpoon Therapeutics, Inc. CIN: 1708493 , United States, Active | Mar 18, 2015 | $25M - $100M (As on Apr 07, 2023) | - | - |
Harpoon Therapeutics, Inc CIN: 47-3458693 , United States, Active | Dec 31, 2014 | - | 99 (As on Feb 28, 2022) | - |
Harpoon Therapeutics's acquisition details
Harpoon Therapeutics got acquired by Merck Sharp & Dohme on Jan 08, 2024 at an acquisition amount of $*****.
Click here to take a look at Harpoon Therapeutics's acquisition in detail
Sign up to download Harpoon Therapeutics' company profile
Harpoon Therapeutics's funding and investors
Harpoon Therapeutics has raised a total funding of $130M over 5 rounds. Its first funding round was on Mar 31, 2016. Its latest funding round was a Post IPO round on Oct 23, 2023 for $*****. 10 investors participated in its latest round. Harpoon Therapeutics has 19 institutional investors.
Here is the list of recent funding rounds of Harpoon Therapeutics:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Oct 23, 2023 | 7087307 | Post IPO | 2993001 | 8883170 | 2367171 | 7135773 |
Mar 28, 2023 | 1815231 | Post IPO | 2433048 | 4873694 | 2440690 | |
Nov 11, 2018 | 2940592 | Series C | 7539582 | 8126281 |
Access funding benchmarks and valuations. Sign up today!View details of Harpoon Therapeutics's funding rounds and investors
Harpoon Therapeutics' founders and board of directors
Founder? Claim ProfileHarpoon Therapeutics' employee count trend
Harpoon Therapeutics has 10 - 49 employees as of Mar 26. Here is Harpoon Therapeutics's employee count trend over the years:
Uncover Harpoon Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Harpoon Therapeutics's Competitors and alternates
Top competitors of Harpoon Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Harpoon Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
779th | Harpoon Therapeutics 2015, Cambridge (United States), Acquired | Developer of T-cell antibodies against hematologic and solid tumor targets | $130M | 45/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Harpoon Therapeutics's competitors? Click here to see the top ones
Harpoon Therapeutics's Investments and acquisitions
Harpoon Therapeutics has made no investments or acquisitions yet.
Reports related to Harpoon Therapeutics
Here is the latest report on Harpoon Therapeutics's sector:
News related to Harpoon Therapeutics
Filter this list•
•
•
Merck completes acquisition of Harpoon TherapeuticsInvesting•Mar 11, 2024•Merck, Harpoon Therapeutics, Merck Sharp & Dohme
•
Halper Sadeh LLC Investigates AMAM, HARP, JNPR, TGANGlobeNewswire•Feb 10, 2024•Halper Sadeh, Transphorm, Juniper Networks, Harpoon Therapeutics and 1 other
•
Halper Sadeh Llc Investigates Harp, Taro, FfnwBenzinga•Feb 07, 2024•Halper Sadeh, Harpoon Therapeutics, Taro, First Financial Northwest Bank
•
•
Merck’s $680 Million Acquisition Of Harpoon TherapeuticsGlobal Legal Chronicle•Jan 23, 2024•Merck, Harpoon Therapeutics, Centerview Partners, Covington & Burling and 1 other
•
The M&A Class Action Firm Continues Investigating the Merger – GRCL, AXNX, HARP, CVLYGlobeNewswire•Jan 20, 2024•Monteverde, PeoplesBank, Harpoon Therapeutics, Axonics and 1 other
•
•
Arix Bioscience Eyes $19 Million Return From Harpoon SaleAJ Bell•Jan 19, 2024•Arix Bioscience, Harpoon Therapeutics
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Harpoon Therapeutics
Explore our recently published companies
- Carrs Group - Carlisle based, 1831 founded, Public company
- Hegadus - United Kingdom based, 2014 founded, Unfunded company
- Maria Linden - Sweden based, Unfunded company
- Click Direct Pay - Unfunded company
- your landing page sucks - 2017 founded, Unfunded company
- BUSTPER - Spain based, 1973 founded, Unfunded company
